Liquim Limited announces registration on ARTG

Liquim Limited is pleased to announce that our Respi-Viva Nasal Spray and Respi-Viva Oral spray have been entered on the TGA’S ARTG Register of Listed medicines under the numbers AUST L 399835 and AUST L 399836, respectively.

These two newly listed medicine products result from research and the development of nasal and oral sprays for the maintenance and support of nasal and oral mucosa and the upper respiratory tract. The permitted indications for Respi-Viva Nasal Spray are “Maintain / Support healthy mucous membranes / mucous tissue of the respiratory tract and Soothe respiratory tract mucous membranes / mucous tissue”, whilst the permitted indications for Respi-Viva Oral spray include ‘Maintain / Support oral mucous membrane health”.

Both products Respi-Viva Nasal Spray and Respi-Viva Oral Spray are alcohol (ethanol)-free and contain plant-derived ingredients which are on the TGA lists of products deemed safe for human consumption

Neither product is yet available for sale in Australia.  The company is finalising manufacturing agreements with an international cGMP manufacturer and expects that product will ship in Q2 2023.


This website is designed to serve individuals interested in gathering information regarding Liquim Limited for investment or business purposes. The website includes details about products that may have varying availability or trademarks in different countries or for different purposes. If you are looking for information about Liquim products, we recommend you visit the dedicated product website in your country of residence. It's important to note that nothing presented on this website should be construed as solicitation, promotional material, or advertising for any product, including those in development. Furthermore, the information provided on this website is not intended to offer medical advice, and it should not be used as a substitute for guidance from a qualified healthcare professional or physician.